respiratory syncytial virus (RSV)

November 15, 2021

Who’s who in the respiratory landscape

A metatranscriptomics method developed by Vanderbilt researchers simultaneously characterizes viruses, microbiome and host response in nasal swabs, opening opportunities to explore molecular interactions directly in clinical samples.

By Leigh MacMillan
Mid adult African American female pediatrician uses a tongue depressor to look at her young Filipino patient's throat.
June 23, 2021

Pediatricians see spike in RSV cases, urge parents to be on lookout for symptoms

“We are seeing a spike in respiratory illnesses, especially RSV (respiratory syncytial virus) and parainfluenza, which cause croup and bronchiolitis in young children and flu-like symptoms in older children and adults,” said James Antoon, MD, PhD, FAAP, assistant professor of Pediatrics at Children’s Hospital at Vanderbilt.

By Jessica Pasley
November 14, 2019

RSV transmission in the Middle East

Understanding how RSV is transmitted, which strains dominate and how new strains emerge around the globe will guide better vaccine and anti-viral drug design.

By Laura Powell
July 12, 2018

Team explores diabetes drug’s ability to treat RSV infection

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

By Leigh MacMillan
little girl using inhaler
March 1, 2018

Study sheds light on how childhood RSV can lead to asthma

Infants who have higher amounts of the bacterium Lactobacillus present in their nose or upper part of the throat during an acute respiratory syncytial virus (RSV) infection are less likely to develop childhood wheezing later in life, a new Vanderbilt-led Center for Asthma Research study found.

By Christina Echegaray
February 23, 2018

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

By Bill Snyder
May 15, 2017

RSV-HRV viral interference

RSV infection reduces the risk of infection with human rhinovirus, which could have implications for vaccine development and prevention strategies for viral respiratory tract infections in infants.
By Leigh MacMillan
February 9, 2017

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
By Bill Snyder
October 20, 2016

Research sheds light on how RSV wards off potential vaccines

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.
By Bill Snyder
July 21, 2016

Team to study RSV’s role in asthma formation

Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).
By VUMC News and Communications
April 2, 2015

Gene variant, environment can boost RSV severity

A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found.
By Leigh MacMillan
February 26, 2015

Respiratory viruses are main childhood pneumonia culprit: Study

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine.
By Christina Echegaray
July 17, 2014

Study identifies antibody that may fight MPV, RSV

New Vanderbilt-led research published in the Journal of Infectious Diseases has identified an antibody that shows promise in preventing and treating human metapneumovirus (MPV) and respiratory syncytial virus (RSV) — the two leading causes of respiratory infections in young children.
By Christina Echegaray
1 2 3